Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01610 ...
Drug Name Valganciclovir
Molecular Weight 354.3617
Molecular Formula C14H22N6O5
CAS Number 175865-60-8
SMILES CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O
External Links
DRUGBANK DB01610
PubChem Compound 64147
PDR 2146
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Not Available

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 60.0 % 60 % Tablet, PO, oral; food; DRUGBANK
Bioavailability 61.0 % 61±9 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 200.0 ng/ml 0.20±0.7 mcg/ml PO, oral; food; The Pharmacological Basis of Therapeutics
C Max 5600.0 ng/ml 5.6±1.5 mcg/ml PO, oral; Drug form; food; The Pharmacological Basis of Therapeutics
T Max 0.50 h 0.5±0.3 h PO, oral; food; The Pharmacological Basis of Therapeutics
T Max 2.0 h 1-3 h PO, oral; Drug form; food; The Pharmacological Basis of Therapeutics
Clearance 0.18 L/h/kg 3.07±0.64 ml/min/kg intravenous injection, IV; DRUGBANK
Clearance 5.3 L/h 5.3±0.9 L/h mild renal function; patients; DRUGBANK
Volume of Distribution 0.70 L/kg 0.703±0.134 L/kg DRUGBANK
Half-life 4.1 h ~4.08 h RD, renal impairment, Renal disease，including uremia ↑ ; DRUGBANK
Half-life 0.50 h 0.5±0.2 h PO, oral; Male, men;  Female, women; viral infections; The Pharmacological Basis of Therapeutics
Half-life 3.7 h 3.7±0.6 h Metabolite; PO, oral; Male, men;  Female, women; viral infections; RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 0.50 h 0.5 h elimination half-life; The Pharmacological Basis of Therapeutics
Protein Binding 1.5 % 1-2 % plasma proteins; DRUGBANK

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for neonates 32.0 mg/kg/day 32 mg/kg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for infants 32.0 mg/kg/day 32 mg/kg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for children 900.0 mg/day 900 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for children 1800.0 mg/day 1800 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adolescents 900.0 mg/day 900 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adolescents 1800.0 mg/day 1800 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adolescents 900.0 mg/day 900 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adolescents 1800.0 mg/day 1800 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adults 900.0 mg/day 900 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for adults 1800.0 mg/day 1800 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for geriatric 900.0 mg/day 900 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR
Max dose for geriatric 1800.0 mg/day 1800 mg/day PO, oral Valcyte valganciclovir hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1